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acts to decrease serum uric acid through
inhibition of urate transporters in the
kidney
Jeffrey Miner1*, Philip K. Tan1, David Hyndman1, Sha Liu1, Cory Iverson1, Payal Nanavati1, David T. Hagerty1,
Kimberly Manhard1, Zancong Shen1, Jean-Luc Girardet1, Li-Tain Yeh1, Robert Terkeltaub2 and Barry Quart1
Abstract
Background: Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes
hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of
serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone are used as gout therapies;
however, their use is limited by drug–drug interactions and off-target toxicity, respectively. Here, we define the
mechanism of action of lesinurad (Zurampic®; RDEA594), a novel URAT1 inhibitor, recently approved in the USA
and Europe for treatment of chronic gout.
Methods: sUA levels, fractional excretion of uric acid (FEUA), lesinurad plasma levels, and urinary excretion of
lesinurad were measured in healthy volunteers treated with lesinurad. In addition, lesinurad, probenecid, and
benzbromarone were compared in vitro for effects on urate transporters and the organic anion transporters (OAT)1
and OAT3, changes in mitochondrial membrane potential, and human peroxisome proliferator-activated receptor
gamma (PPARγ) activity.
Results: After 6 hours, a single 200-mg dose of lesinurad elevated FEUA 3.6-fold (p < 0.001) and reduced sUA levels
by 33 % (p < 0.001). At concentrations achieved in the clinic, lesinurad inhibited activity of URAT1 and OAT4 in vitro,
did not inhibit GLUT9, and had no effect on ABCG2. Lesinurad also showed a low risk for mitochondrial toxicity and
PPARγ induction compared to benzbromarone. Unlike probenecid, lesinurad did not inhibit OAT1 or OAT3 in the
clinical setting.
Conclusion: The pharmacodynamic effects and in vitro activity of lesinurad are consistent with inhibition of URAT1
and OAT4, major apical transporters for uric acid. Lesinurad also has a favorable selectivity and safety profile,
consistent with an important role in sUA-lowering therapy for patients with gout.
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Background
Gout is a urate crystal deposition disease that results from
a metabolic disorder, hyperuricemia (elevated serum uric
acid (sUA)), and the consequent deposition of monoso-
dium urate crystals in joints, soft tissues, and organs [1].
Gout is a major health problem and is increasing in preva-
lence in the USA and many other countries [2–7]. Primary
prevention and treatment of gout includes measures to
keep sUA levels below 6 mg/dL [8–12]. Diminished renal
clearance of uric acid promotes hyperuricemia in at least
90 % of patients with gout [13]. Thus treatment with an
agent that has a uric acid lowering effect by increasing
urinary excretion could be useful in these patients.
Renal factors contributing to hyperuricemia include sin-
gle or combined effects of decreased glomerular filtration
rate, drug-induced increases in renal urate reabsorption,
and altered expression and/or function of renal urate
transporters [14]. Serum urate is normally filtered by the
glomerulus, with near complete reabsorption in the
kidney proximal tubule [15]. Genome-wide association
studies show that multiple renal urate transporters con-
tribute to the regulation of sUA levels [16–18], and gen-
etic loss of function studies indicate that URAT1
(SLC22A12) and GLUT9 (SLC2A9) play significant roles
in renal reabsorption of urate, as patients with disruptive
mutations in these transporters have high fractional excre-
tion of uric acid (FEUA) and hypo-uricemia [19–23]. Or-
ganic anion transporter (OAT)4, is another urate
transporter that has been genetically associated with
hyperuricemia and gout [18, 24], and with an increased
risk of hyperuricemia and gout induced by treatment with
diuretics [25–28].
Management approaches to hyperuricemia in gout in-
clude not only xanthine oxidase inhibitor (XOI) mono-
therapy and uricase therapy for refractory disease, but
also URAT1 inhibitors (probenecid and benzbromarone)
in monotherapy or in combination with XO inhibition
[9]. However, probenecid is limited by the need to dose
two to four times daily due to its short half-life. Pro-
benecid also alters the pharmacokinetics (PK) of a wide
variety of other drugs through inhibition of OAT1 and
OAT3 (OAT1/SLC22A6 and OAT3/SLC22A8) [29, 30].
These drug–drug interactions limit probenecid use and
increase the complexity of dosing in combination with
other therapies. Benzbromarone is a highly potent
URAT1 inhibitor that is not available in the USA and
has very limited availability in Europe, because of links
with idiosyncratic, but severe hepatotoxicity [31]. Other
drugs with mild-to-moderate URAT1 inhibition activity,
such as the lipid-lowering agent, fenofibrate, and the
angiotensin receptor blocker, losartan, have been studied
for the treatment of hyperuricemia and gout [32, 33],
but there remains an important clinical need for potent
and selective URAT1 inhibitors. In patients with gout,
restoring normal uric acid excretion with a URAT1 inhibi-
tor in combination with an XOI represents a potentially
powerful approach to lowering sUA [34].
Lesinurad (Fig. 1), a metabolite of another compound
in development, was discovered to be responsible for an
unexpected decrease in sUA levels seen in early clinical
trials. Lesinurad exhibited significant urinary excretion
that was closely correlated with urinary uric acid excre-
tion [35]. These findings suggest that the decreased sUA
was occurring through effects on renal urate handling
caused by lesinurad. A potential target is URAT1, a
transporter known to be associated with uric acid re-
absorption [19]; however, other transporters are also
known to be involved [36]. Lesinurad reduced sUA and
increased fractional excretion of uric acid (FEUA) in a
dose-dependent manner in healthy volunteers after a
single dose, consistent with the inhibition of URAT1 and
OAT4 observed in vitro. Importantly no clinically rele-
vant changes in the PK of lesinurad or the XOIs febuxo-
stat or allopurinol have been detected in patients with
gout [34, 37].
In this study, we define the molecular mechanism of
action of the uric acid reabsorption inhibitor lesinurad
(Zurampic®), previously known as RDEA594. Lesinurad
is an oral agent recently approved in its 200-mg dose by
the US Food and Drug Administration [38] and the
European Commission. It is indicated in combination
with an XOI for the treatment of hyperuricemia associ-
ated with gout in patients who have not achieved target
sUA levels with an XOI alone.
Fig. 1 Structure of lesinurad (RDEA594), 2-((5-bromo-4-(4-
cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio) acetic acid
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Methods
Transporter activity assays
For URAT1 and OAT4, DNA constructs pCMV/neo-
URAT1 and pCMV/neo-OAT4 were purchased from
Origene Technologies. In addition, a glycine codon was
introduced just prior to the stop codon using the Quik-
Change Site-Directed Mutagenesis Kit (Agilent Tech-
nologies) according to the manufacturer’s instructions,
producing pCMV/neo-URAT1-553G and pCMV/neo-
OAT4-551G. The added glycine has no effect on the ac-
tivity of the proteins (data not shown). Stably transfected
HEK293-OAT4-551G cells were used for OAT4 trans-
port activity assays, which were grown for several weeks
in media (DMEM with 10 % fetal bovine serum and
1 mM sodium pyruvate) containing 500 μg/mL geneticin
sulfate. An isolated clone with high OAT4 activity was
selected for activity assays. One day prior to the assay,
cells were plated at 200,000 cells/well into each well of
white, clear bottom poly-D-lysine-coated assay plates
(BD Biosciences). URAT1-553G-expressing cells were
prepared by transient reverse transfection of pCMV/
neo-URAT1-553G into HEK-293 T cells using Dream-
Fect Gold (Boca Scientific) according to the manufac-
turer’s instructions, and plated directly into assay plates
in the same way as the OAT4-551G cells.
The cells were assayed on the following day. For measur-
ing urate transport, cells were washed once with wash buf-
fer (25 mM MES pH 5.5, 125 mM sodium gluconate), and
then incubated in assay buffer (25 mM MES pH 5.5,
125 mM sodium gluconate, 4.8 mM potassium gluconate,
1.2 mM KH2PO4, 1.2 mM MgSO4, 1.3 mM calcium gluco-
nate, and 5.6 mM glucose) containing different amounts of
lesinurad, for 5 minutes: 14C-urate (American Radiolabeled
Chemicals, Inc.) at a final concentration of 100 μM in assay
buffer was then added and incubated with the cells for
10 minutes. The free urate was removed by aspiration and
the cells rinsed three times in 150 μL wash buffer. The cells
were then subjected to liquid scintillation counting to
measure transported urate. Lesinurad dose-response curves
and half-maximal inhibition constants (IC50 values) were
generated from the urate transport results using GraphPad
Prism software (GraphPad Software, Inc.), variable slope
(four parameter) model. Each point represents the mean
and standard error of the mean (SEM) from triplicates.
For OAT1, HEK-293 T cells were transfected as described
above using pSPORT6-hOAT1 (Thermo Scientific) and
assayed for transport of 5 μM 6-carboxyfluorescein (CF) for
2 minutes with or without lesinurad, in assay buffer con-
taining 125 mM NaCl, 4.8 mM KCl, 5.6 mM D-glucose,
1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, and
25 mM HEPES, pH 7.3. The cells were washed three times
in a buffer containing 125 mM NaCl and 25 mM HEPES,
pH 7.3, and then lysed in 1 M sodium hydroxide prior to
fluorescence measurement.
For ABCG2, monolayers of Caco-2 cells expressing
ABCG2 were grown on a permeable support (1 μM PET
membranes) in 24-transwell plates. Cells were washed
and incubated in Hank’s balanced salt solution, with or
without different concentrations of lesinurad or with
100 μM chrysin for 30 minutes at 37 °C in both apical
(A) and basolateral (B) compartments. Each treatment
was assayed in triplicate: [3H]-genistein substrate at 2
nM was then added for an additional 120 minutes at
37 °C. For basolateral-to-apical (B→A) flux measure-
ments, genistein was placed in the basolateral compart-
ment only (donor well) and a sample was taken after the
120-minute incubation period from the apical compart-
ment (receiver well). For apical-to-basolateral (A→ B)
flux measurements, genistein was placed in the apical
compartment only (donor well) and a sample was taken
after the 120-minute incubation period from the basolat-
eral compartment (receiver well). Samples were then
subjected to scintillation counting. The inhibition of
BCRP/ABCG2 was then calculated by the net B→A
flux method [39]. The substrate flux (A→ B or B→A)
is determined by the apparent permeability (Papp) using
the following equation:
Papp ¼ 1= Area  CD 0ð Þð Þ½   dMr=dt:
where Area is the area of the filter in the transwell,
CD(0) is the initial dosing concentration of genistein,
and dMr/dt is the slope of the flux divided by the incu-
bation time.
The net transport in the B→A direction was deter-
mined by subtracting the substrate flux in the A→ B
direction from that in the B→A direction:
Net B→ A flux ¼ Papp B→ Að Þ‐Papp A→Bð Þ:
Percent inhibition is calculated by dividing the Net
(B→A) flux in the presence of the inhibitor by the Net
(B→A) flux in the absence of the inhibitor (inh):
Percent Inhibition ¼ 100 ‐ 100 Net B→Að Þinh=mean Net B→Að Þ
 
:
For GLUT9, SLC2A9v2/GLUT9ΔN in pCMV6/neo
was linearized with XmaI and NotI and cRNA tran-
scribed using the mMessage mMachine T7 kit (Ambion).
Oocytes were injected with either water or 25 ng cRNA
and incubated for 3 to 5 days in ND96 buffer. For each
point, 10 oocytes were incubated with 100 μM 14C-uric
acid in ND96 buffer with and without test compounds
at room temperature for 60 minutes. The oocytes were
then washed three to four times in ice-cold ND96 buffer
and lysed prior to scintillation counting.
Mitochondrial toxicity assay
HepG2 cells were counted via hemocytometer and di-
luted into equal volumes of serum-free Opti-MEM (Life
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Technologies) and JC-1 Staining Solution (Sigma catalog
number CS0390) at 300,000 cells/mL in the presence of
2.5 μg/mL JC-1. Cells were incubated at 37 °C and 5 %
CO2 for 20 minutes, rinsed once with Hank's Balanced
Salt Solution, and resuspended to the same concentra-
tion in serum-free Opti-MEM. Cells were then seeded
into 96-well black-sided clear-bottom tissue culture
plates at 30,000 cells/100 μL/well. Three replicates per
experimental condition group were used. Compound
was added with the final dimethyl sulfoxide (DMSO)
concentration at 0.5 %. After 2 hours at 37 °C and 5 %
CO2, medium was aspirated and plates were read on a
Gemini EM spectrofluorometer (Molecular Devices).
Fluorescence of JC-1 monomers was monitored by exci-
tation at 490 nm and emission at 530 nm (green) and of
aggregates by excitation at 525 nm and emission at
590 nm (red). The ratio of J-aggregates to monomers
was calculated, with a lower ratio indicating increased
cell toxicity. The percent change in mitochondrial mem-
brane potential (Ψm) was calculated as follows:
[Em590/Em530 (vehicle only) – Em590/Em530 (test com-
pound)]/[Em590/Em530 (vehicle only) – Em590/Em530
(100 μMmenadione)].
Human peroxisome proliferator-activated receptor
gamma assay
This assay was performed using nonhuman mammalian
cells engineered to provide a PPARγ-responsive lucifer-
ase reporter gene and constitutive, high levels of PPARγ
(Indigo Biosciences catalog number IB00101). Cells were
incubated with compounds for 24 hours, and then lucif-
erase activity was measured using a luminometer. Agon-
ist activity was reported as fold activation over a vehicle
control. A positive control agonist, rosiglitazone, was in-
cluded in each batch run to verify cell integrity.
Clinical studies
Lesinurad effects on FEUA
From a phase 1 clinical trial, RDEA594-109, eight
healthy male volunteers were administered single oral
doses of 200, 400, or 600 mg lesinurad tablets (with
food). In each treatment period, plasma samples were
collected within 30 minutes before dosing (pre-dose)
and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 30, 36,
and 48 hours post-dose. Urine (total catch) was collected
pretreatment at hours –24 to –18, –18 to –12, and –12
to 0, and post-dose at hours 0 to 6, 6 to 12, 12 to 24, 24
to 30, 30 to 36, and 36 to 48.
After protein precipitation of the samples, lesinurad
levels in plasma and urine were measured at Ardea Biosci-
ences by quantitative high performance liquid chromatog-
raphy with tandem mass spectrometry. The lesinurad
plasma PK parameters maximum plasma concentration
(Cmax) and area under the curve (AUC) were derived
using the software WinNonlin Professional, Version 5.2
(Pharsight Corporation). The parameters from individual
profiles of lesinurad were determined using noncompart-
mental methods. Urine samples were analyzed for uric
acid and creatinine using enzymatic methods by Covance
Clinical Research Unit (Dallas, TX, USA), and pharmaco-
dynamic (PD) parameters were determined by Covance
Clinical Research Unit using SAS, Version 8.2 (SAS Insti-
tute Inc). Calculated PD parameters for uric acid included
urinary excretion, renal clearance, and FEUA. FEUA was
calculated by dividing the uric acid clearance by the cre-
atinine clearance. For analyzing the relationship between
plasma lesinurad concentrations and FEUA, the weighted
average plasma lesinurad concentration was calculated for
plasma samples from each time period that corresponded
to the associated urine samples.
Lesinurad effects on sUA
Serum was collected within 30 minutes prior to drug ad-
ministration, and at 6, 12, 16, 24, 30, 36, and 48 hours
after dosing. Serum urate levels and PD parameters were
assayed and calculated by Covance Clinical Research
Unit as described above.
Results
Clinical effects on urate handling and pharmacokinetics
of lesinurad
To determine the effects of lesinurad on urate handling, the
levels of uric acid and lesinurad were measured in the blood
and urine in healthy volunteers (Fig. 2). Lesinurad produced
a dose-dependent increase in FEUA, a measure of the relative
amount of uric acid excreted by the kidneys (Fig. 2a). After
a single 200-mg, 400-mg, and 600-mg dose of lesinurad, the
FEUA increased from a baseline of 5.8 % to a peak of 21.8,
26.7, and 32.3 %, respectively, within 6 hours, and then
dropped to baseline levels by 24 hours. FEUA increased with
lesinurad plasma concentrations (Fig. 2b). The half-maximal
effective plasma concentration of lesinurad for elevating
FEUA was 13 μM, and some individuals with high plasma
lesinurad had up to 35 % FEUA. In accord with the increases
in FEUA, single doses of lesinurad led to a dose-dependent
reduction in sUA (Fig. 2c). The highest 600-mg dose of lesi-
nurad reduced sUA by a maximum of 42 % after 6 hours,
and this was sustained at 31 % after 24 hours. The lower
200-mg and 400-mg dose of lesinurad also reduced sUA
dramatically, albeit less so compared with the 600-mg dose.
Therefore, lesinurad increased the renal excretion of uric
acid and lowered sUA. In addition, lesinurad underwent ac-
tive urinary excretion, which correlated linearly with the
plasma concentration of lesinurad (Fig. 2d).
Inhibition of reabsorptive urate transporters by lesinurad
The urate transporters URAT1, OAT4, and GLUT9 are
all genetically associated with sUA and promote the
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reabsorption of uric acid from the kidney proximal tu-
bule. The urate-lowering gout therapies benzbromarone
and probenecid block renal reabsorption of uric acid
and are known URAT1 inhibitors. We measured the po-
tency of lesinurad, benzbromarone, and probenecid
against URAT1 and OAT4 (Table 1 and Fig. 3). Lesi-
nurad inhibited the urate-transport activity of URAT1
and OAT4 in a dose-dependent manner and at a similar
potency, with an IC50 of 3.53 and 2.03 μM, respectively
(Fig. 3a). Benzbromarone inhibited URAT1 and OAT4
with an IC50 of 0.29 and 3.19 μM, respectively (Fig. 3b).
Probenecid inhibited both transporters equipotently at
13.23 (URAT1) and 15.54 (OAT4) μM, but with lower
potency than lesinurad (Fig. 3c). Lesinurad at up to
100 μM had no effect on GLUT9 (Fig. 3d). Benzbromar-
one had only weak activity on GLUT9 and is not likely
to be active in vivo on this transporter.
Transporters involved in urate secretion and drug–drug
interactions
ABCG2, OAT1, and OAT3 are important in the renal se-
cretion of many drugs, endogenous organic compounds
including uric acid, xenobiotics, and toxins [30, 40].
Therefore, we measured the potency of lesinurad against
these transporters (Table 2 and Fig. 4). Lesinurad inhibited
OAT1 with an IC50 of 3.90 μM (Fig. 4a) and OAT3 with
an IC50 of 3.54 μM (previously reported in Shen et al.
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Fig. 2 Effects of lesinurad on urate handling and lesinurad
pharmacokinetics in healthy human volunteers. a Dose-dependent
increase in fractional excretion of uric acid (FEUA) after a single 200-mg,
400-mg, or 600-mg dose of lesinurad. FEUA was elevated from baseline
(–18 to 0 hours) at 0–6 hours after dosing and then returned to normal
after 24 hours. For all doses, p < 0.001 at 0–6 hours and 6–12 hours
relative to baseline. b FEUA levels increased with increasing plasma
lesinurad. The half-maximal effective concentration of plasma lesinurad
concentrations on FEUA was 13 μM. Results are from healthy volunteers
on a single 200-mg, 400-mg, or 600-mg dose of lesinurad. c Healthy
volunteers on a single 200-mg, 400-mg, or 600-mg dose of lesinurad
had a dose-dependent decrease in serum uric acid (sUA), for every
drug treatment point for all doses relative to baseline, p <0.001. d
Urinary excretion of lesinurad correlated linearly with plasma lesinurad
following a single dose of 200, 400, or 600 mg lesinurad. AUC area
under the curve for plasma concentration vs. time
Table 1 Potencies (μM, mean ± SEM) of lesinurad, benzbromarone,
and probenecid against the resorptive uric acid transporters URAT1,
OAT4, and GLUT9
Reabsorptive uric acid transporter
Compound URAT1 OAT4 GLUT9
Lesinurad 3.53 ± 0.52 2.03 ± 0.66 >100
Benzbromarone 0.29 ± 0.06 3.19 ± 1.04 ~100
Probenecid 13.23 ± 0.44 15.54 ± 3.39 ND
Results are from three experimentsfree concentration
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[41], and shown in Additional file 1: Figure S1). Lesinurad
at up to 100 μM had no effect on ABCG2 (Fig. 4b).
Although lesinurad inhibits URAT1, OAT1, and OAT3
at a similar potency, lesinurad does not inhibit OAT1 or
OAT3 in vivo [41]. For a single 200-mg dose of lesi-
nurad, the maximal plasma concentration is 29 μM and
due to extensive 98.4 % plasma protein binding [41], the
predicted maximal plasma-free concentration is only
0.46 μM. This concentration is insufficient to inhibit
OAT1 (Fig. 4a, dashed line).
Mitochondrial toxicity
Benzbromarone was never approved in the USA and was
withdrawn from the European market after reports of
drug-associated hepatotoxicity. Subsequently, it was dem-
onstrated that it affects multiple mitochondrial functions
that lead to mitochondrial toxicity in the human liver
carcinoma cell line HepG2 and to apoptosis of rat hepato-
cytes [42]. Lesinurad was tested for mitochondrial toxicity
with benzbromarone and probenecid in HepG2 cells
(Fig. 5a). Consistent with its reported hepatotoxicity,
benzbromarone reduced the mitochondrial membrane po-
tential, a measure of mitochondrial toxicity, at concentra-
tions as low as 0.4 μM and with a half maximal effective
concentration of 1.36 μM. Although these levels are below
the estimated plasma free levels, it is possible that
benzbromarone and its main metabolite benzarone are
concentrated to toxic levels in hepatocytes, as they are ex-
creted primarily through the bile [43]. In contrast, lesi-
nurad showed no mitochondrial toxicity even at the
highest concentration (33 μM) tested. Probenecid showed
no mitochondrial toxicity up to 300 μM.
Peroxisome proliferator-activated receptor gamma
(PPARγ) activation
PPARγ activation is associated with increased cardiovas-
cular risk [44] and benzbromarone is known to activate
PPARγ [45]. Therefore, lesinurad was tested for PPARγ
activation in a cell-based reporter assay and showed no
PPARγ agonism up to 100 μM (Fig. 5b), well above the
Cmax of lesinurad (Table 1). In contrast, benzbromarone
strongly activated PPARγ at 30 μM, similar to previous
results [45]. Probenecid showed a slight PPARγ activa-
tion at 300 μM but no activation at 100 μM or lower.
Discussion
Lesinurad is a URAT1 inhibitor approved for the treat-
ment of hyperuricemia associated with gout in combin-
ation with an XOI. This compound is an orally available
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Fig. 3 Lesinurad inhibits URAT1 and OAT4 urate-transport activity with equal potency, and does not inhibit GLUT9. Urate transport was measured
in cells expressing URAT1-553G (closed circles) or OAT4-551G (triangles) treated with different amounts of lesinurad (a) (left panel), benzbromarone
(b) (center panel), or probenecid (c) (right panel). Untransfected cells (b) (open circles) were used to reveal the background uric acid transport in
the cells. Results are from a single experiment and are representative of multiple experiments. Each point is from samples performed in triplicate, presented
as mean ± SEM. d Lesinurad does not inhibit GLUT9. Urate transport was measured in oocytes injected with water and treated with dimethyl sulfoxide
(DMSO) (open bar), or in oocytes injected with cRNA expressing GLUT9 (SLC2a9v2/GLUT9ΔN) (solid bars) and either treated with DMSO, 100 μM
benzbromarone, or 100 μM lesinurad. Benzbromarone inhibited GLUT9, as shown previously [21, 55]. Results are shown in mean ± SEM. SLC2A9v1/
GLUT9 was also examined, yielding similar results. UA uric acid
Table 2 Potency of lesinurad (μM, mean ± SEM) against the
secretory uric acid transporters OAT1 and ABCG2
Secretory uric acid transporter
Compound OAT1 ABCG2
Lesinurad 3.90 ± 0.94 >100
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small molecule with a structure unrelated to other
known uricosuric agents. Clinical trials in healthy volun-
teers indicate that a single dose of lesinurad increases
FEUA in an exposure-dependent manner and that lesi-
nurad treatment significantly reduces sUA (Fig. 2) [34,
35, 37]. Lesinurad reaches effective concentrations in the
kidney due to active renal excretion and urinary concen-
tration (Fig. 2d) consistent with the report that approxi-
mately one third of the compound is excreted via urine
[35]. This information prompted the current investiga-
tion, in which the effects of lesinurad on the key genetic-
ally validated uric acid reabsorption transporters,
URAT1, GLUT9, and OAT4 [18–24], were evaluated,
demonstrating significant inhibitory activity of lesinurad
on both OAT4 and URAT1, but not GLUT9.
The clinical effect of increasing fractional excretion of
uric acid by lesinurad is consistent with inhibition of
OAT4 and URAT1. Lesinurad-mediated inhibition of
these transporters is consistent with increasing urinary uric
acid excretion, and its OAT4 activity in particular may
counteract diuretic-induced hyperuricemia [46, 47]. Clinical
trials confirm that lesinurad adequately reduces sUA in the
presence of co-administered diuretics [46, 47]. URAT1 is
also the primary target of the other antihyperuricemic
agents, benzbromarone and probenecid [19]. Lesinurad has
a higher potency for URAT1 compared with probenecid
(Fig. 3). The pharmacologic effect of benzbromarone as a
URAT1 inhibitor is consistent with its estimated plasma
concentration of 0.016–0.16 μM [48, 49]. Thus, benzbro-
marone is unlikely to inhibit GLUT9 and OAT4 due to its
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OAT1. Cells transfected with control plasmid (pSPORT6, open circles)
or OAT1-expressing plasmid (pSPORT6-hOAT1) were incubated with
different concentrations of lesinurad. Data are from an individual
representative experiment, shown as the mean ± SEM of samples in
triplicate. The dashed line indicates the maximum plasma- free
concentration (Cmax,free) of a single 200-mg dose of lesinurad
obtained in the clinic. This concentration does not inhibit OAT1 in
vitro. b Lesinurad does not affect ABCG2 activity. Caco-2 cells were
either untreated or treated with the indicated concentrations of lesi-
nurad (open bars) for 30 minutes prior to the addition of the ABCG2
substrate genistein for 120 minutes. The inhibitor chrysin was used
as a positive control (solid bar). Results are the mean ± SEM from
samples in triplicate
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Fig. 5 Lesinurad is not toxic to mitochondria (a) and does not
induce peroxisome proliferator-activated receptor gamma (PPARγ)
(b). Different doses of lesinurad (closed squares), benzbromarone
(open triangles), or probenecid (open squares) were incubated with cells.
a Mitochondrial membrane potential was measured in HepG2 cells.
Lesinurad and probenecid did not change the membrane potential at
any of the doses tested, whereas benzbromarone at the same
concentrations altered the membrane potential in a dose-dependent
manner, indicative of mitochondrial toxicity. Each point was performed
in triplicate and is presented as mean ± SEM. b PPARγ activation was
measured in cells expressing a PPARγ-responsive reporter gene.
Lesinurad has no effect, although probenecid mildly induces PPARγ at
the highest concentration tested. Benzbromarone strongly induces
PPARγ activity. The effects of benzbromarone on perturbing hepatic
mitochondrial function and activating PPARγ may lead to hepatotoxicity
and cardiovascular events, respectively
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lower potency against these transporters (Table 1, Fig. 3b
and d), low plasma concentration, and low (6 %) urinary ex-
cretion [43].
In addition to uric acid secretion, OAT1 and OAT3
are also involved in many drug–drug interactions, and
hence the US Food and Drug Administration requires
evaluation of the effects of new drug candidates on the
activity of these transporters [50]. Despite the inhibitory
activity of lesinurad on OAT1 and OAT3 in vitro, there
is no effect of lesinurad on the renal clearance and PD
of the OAT substrate furosemide, showing that lesinurad
does not inhibit these secretory drug transporters in vivo
[41]. This is in stark contrast to probenecid, which alters
the PK and renal excretion of furosemide through OAT1
and OAT3 [51, 52]. Probenecid is an inhibitor of OAT1
and OAT3, and its use is limited in part due to clinically
significant OAT1/OAT3-dependent drug–drug interac-
tions [30, 53]. Plasma protein binding of lesinurad at
98.4 % [41] leads to maximal plasma-free concentrations
that are insufficient to inhibit OAT1 (Fig. 4a), likely ac-
counting for this important clinical difference between
probenecid and lesinurad. Therefore, the in vivo profile
of lesinurad in the human renal tubule (Fig. 6) shows in-
hibition of both URAT1 and OAT4 (unlike benzbromar-
one, which inhibits only URAT1) and no inhibition of
OAT1 and OAT3 (unlike probenecid, which inhibits
URAT1, OAT4, OAT1, and OAT3).
In addition to OAT1 and OAT3, the renal proximal
tubule expresses a number of additional urate trans-
porters that potentially participate in urate secretion
(Fig. 6) [18, 54]. Activation of this secretory pathway could
theoretically promote the observed pharmacodynamic
effects of lesinurad (elevated FEUA and lowered sUA).
Lesinurad does not activate either OAT1 or ABCG2 (Fig. 4),
two participants in the secretion of uric acid. The impact of
lesinurad on other transporter candidates involved in urate
secretion remains untested.
Testing benzbromarone-related endpoints, we found
that lesinurad and probenecid have no effect on mito-
chondrial activity, in contrast to benzbromarone, which
severely disrupts mitochondrial integrity in human hepa-
tocytes at and above 0.4 μM. Similarly, with respect to
PPARγ activity - and in contrast with benzbromarone -
lesinurad and probenecid demonstrated no effect at up
to 100 μM, thus, likely having no clinical effect based on
the Cmax of lesinurad. Benzbromarone is a known
PPARγ agonist, and although no long-term cardiovascu-
lar studies have been conducted with benzbromarone,
activity on this nuclear receptor is associated with in-
creased adverse cardiovascular events [44].
Conclusions
The action of lesinurad counteracts the inadequate ex-
cretion of uric acid commonly found in patients with
gout. The potential to combine two mechanisms of
treatment, inhibition of uric acid production with XOIs
and inhibition of uric acid reabsorption with a selective
uric acid reabsorption inhibitor, represents a powerful
approach to the reduction of sUA. Lesinurad had signifi-
cant URAT1 and OAT4 inhibitory activity, likely ac-
counting for its PD effect, as well as a favorable
selectivity profile in vitro compared with other drugs
that inhibit uric acid reabsorption. The compound is a
new treatment option for hyperuricemia associated with
gout in combination with XOIs.
Benzbromarone
Probenecid
Lesinurad
Organic anions
OAT1
OAT3
GLUT9
NPT4
NPT1
OAT4
URAT1
Urate
Urate
Urate
Urate
Urate
Organic anions
Diuretics
Urate
Blood Urine
Organic
anions
Fig. 6 Lesinurad blocks URAT1 and OAT4 to enhance fractional excretion of uric acid and reduce serum urate levels. This diagram of a nephron
depicts the location of urate transporters within the proximal tubule epithelial cell, and the mechanism of action of lesinurad compared to
benzbromarone and probenecid. Lesinurad inhibits urate reabsorptive importers URAT1 and OAT4, and the inhibition of OAT4 may counteract
postulated OAT4-dependent diuretic-induced hyperuricemia. Benzbromarone specifically inhibits URAT1 but not OAT4. Probenecid nonspecifically inhibits
URAT1, OAT4, and other OAT family members, leading to drug–drug interactions involving OAT1 and OAT3. At physiologically relevant concentrations,
none of these compounds inhibits GLUT9, another transporter that is important for the renal reabsorption of urate [18–21]
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